Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Celularity Inc. (CELU)

2.95   -0.04 (-1.34%) 08-18 06:17
Open: 2.99 Pre. Close: 2.99
High: 3.03 Low: 2.9
Volume: 424,171 Market Cap: 420(M)
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.05 - 3.08 3.08 - 3.1
Low: 2.84 - 2.88 2.88 - 2.9
Close: 2.91 - 2.97 2.97 - 3.01

Technical analysis

as of: 2022-08-17 4:22:09 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.35     One year: 5.08
Support: Support1: 2.72    Support2: 2.26
Resistance: Resistance1: 3.72    Resistance2: 4.34
Pivot: 3.04
Moving Average: MA(5): 3.03     MA(20): 3.15
MA(100): 6.51     MA(250): 6.41
MACD: MACD(12,26): -0.3     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 29     %D(3): 31.1
RSI: RSI(14): 37.7
52-week: High: 13.18  Low: 2.72
Average Vol(K): 3-Month: 646 (K)  10-Days: 586 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CELU ] has closed above bottom band by 30.5%. Bollinger Bands are 88.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Mon, 15 Aug 2022
Q3 2022 EPS Estimates for Celularity Inc. (NASDAQ:CELU) Lifted by Oppenheimer - MarketBeat

Fri, 05 Aug 2022
Is Celularity Inc (CELU) Stock About to Get Hot Friday? - InvestorsObserver

Tue, 19 Jul 2022
Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform - PR Newswire

Sun, 17 Jul 2022
Celularity Inc. (NASDAQ:CELU) Short Interest Up 50.5% in June - MarketBeat

Tue, 14 Jun 2022
Is Celularity Inc (CELU) Stock a Smart Value Tuesday? - InvestorsObserver

Wed, 08 Jun 2022
Celularity to be added to the Russell 3000, Small-Cap Russell 2000 - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 142 (M)
Shares Float 52 (M)
% Held by Insiders 71.3 (%)
% Held by Institutions 20.3 (%)
Shares Short 3,030 (K)
Shares Short P.Month 1,980 (K)

Stock Financials

EPS -0.88
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.64
Profit Margin (%) 0
Operating Margin (%) -612.5
Return on Assets (ttm) -22.5
Return on Equity (ttm) -580
Qtrly Rev. Growth 123
Gross Profit (p.s.) 0.08
Sales Per Share 0.17
EBITDA (p.s.) -1
Qtrly Earnings Growth 0
Operating Cash Flow -119 (M)
Levered Free Cash Flow -55 (M)

Stock Valuations

PE Ratio -3.4
PEG Ratio 0
Price to Book value 4.53
Price to Sales 17.06
Price to Cash Flow -3.53

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.